Familial Mediterranean Fever Pharmaceuticals Market Report 2026

Familial Mediterranean Fever Pharmaceuticals Market Overview

• Familial Mediterranean Fever Pharmaceuticals market size has reached to $1.72 billion in 2025 • Expected to grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.1% • Growth Driver: Rise In Gene Therapy Driving The Growth Of The Market Due To Advancements In Genetic Engineering • Market Trend: R-Pharm Group's Goflikicept Receives FDA Orphan Drug Designation, Advancing IL-1 Blockade Therapy for Familial Mediterranean Fever • Middle East was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Familial Mediterranean Fever Pharmaceuticals Market?

Familial mediterranean fever (FMF) pharmaceuticals refer to medications used to manage and treat FMF, a genetic disorder characterized by recurrent fever and inflammation, often affecting the abdomen, chest, and joints. The primary goal of these pharmaceuticals is to reduce the frequency and severity of attacks and prevent long-term complications, such as amyloidosis. The main familial mediterranean fever pharmaceuticals are colchicine, interleukin-1 inhibitors, and anti-il-6 drugs. Colchicine is a medication that helps reduce inflammation and prevent flare-ups in conditions like gout and other inflammatory disorders. It can be administered through both oral and injectable channels and is used by various end users including hospitals, clinical diagnostic laboratories, and others.

What Is The Familial Mediterranean Fever Pharmaceuticals Market Growth Forecast?

The familial mediterranean fever pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rising diagnosis rates outside endemic regions, growing adoption of biologics, expansion of orphan drug programs, improved genetic screening, increasing focus on long-term complication prevention. Major trends in the forecast period include continued reliance on colchicine therapy, increasing use of interleukin-1 inhibitors, expansion of biologic treatments for resistant FMF, growing focus on preventing amyloidosis, improved genetic diagnosis supporting early treatment.

Global Familial Mediterranean Fever Pharmaceuticals Market Segmentation

1) By Drug Type: Colchicine, Interleukin-1 Inhibitors, Anti-IL-6 Drugs 2) By Route Of Administration: Oral, Injectable 3) By End Users: Hospitals, Clinical Diagnostic Laboratories, Other End Users Subsegments: 1) By Colchicine: Oral Colchicine, Intravenous Colchicine 2) By Interleukin-1 Inhibitors: Anakinra, Canakinumab, Rilonacept 3) By Anti-IL-6 Drugs: Tocilizumab, Off-Label IL-6 Receptor Antagonists, Refractory FMF Supportive IL-6 Modulation

What Is The Driver Of The Familial Mediterranean Fever Pharmaceuticals Market?

The rise in gene therapy is expected to drive the growth of the familial Mediterranean fever (FMF) pharmaceuticals market going forward. Gene therapy is a medical approach that modifies or replaces faulty genes to treat or prevent diseases at the genetic level. The rise in gene therapy is due to advancements in genetic engineering, which enable precise targeting and correction of genetic disorders, offering potential cures for previously untreatable diseases. Gene therapy positively impacts familial mediterranean fever (FMF) pharmaceuticals by targeting the root cause mutations in the MEFV (Mediterranean fever) gene, potentially providing a long-term or permanent cure rather than symptom management. For instance, in July 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit organization, 76 gene therapy trials were initiated in the second quarter of 2024, a 25% increase from the previous quarter. Therefore, the rise in gene therapy is driving the growth of the familial Mediterranean fever (FMF) pharmaceuticals market.

Key Players In The Global Familial Mediterranean Fever Pharmaceuticals Market

Major companies operating in the familial mediterranean fever pharmaceuticals market are Novartis International AG, Swedish Orphan Biovitrum AB, Granules Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Camber Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Indena S.p.A., Harman Finochem, Alchem International, Honour Lab Ltd., Maithri Drugs Pvt. Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma, R-Pharm Group, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited

Global Familial Mediterranean Fever Pharmaceuticals Market Trends and Insights

Major companies operating in the familial mediterranean fever pharmaceuticals market are focusing on targeted biologic therapies, such as dual interleukin-1 (IL-1α and IL-1β) blockade mechanisms and orphan drug designation pathways, to achieve sustained disease remission and expand treatment options for patients with autoinflammatory disorders. Dual interleukin-1 blockade mechanisms involve heterodimeric hybrid proteins that simultaneously bind with high affinity to both IL-1α and IL-1β cytokines, effectively neutralizing the inflammatory cascade that drives disease pathogenesis in familial Mediterranean fever and related conditions. For instance, in November 2024, R-Pharm Group, a Russia-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for Goflikicept, a novel heterodimeric hybrid protein targeting both IL-1α and IL-1β, for the treatment of familial Mediterranean fever (FMF) and idiopathic recurrent pericarditis (IRP). The company completed Phase 2/3 clinical trials for IRP and obtained marketing authorization in Russia, while advancing a Phase 2 study for FMF across Turkey, Russia, and Armenia, establishing IL-1 blockade as a leading mechanism for sustained remission in autoinflammatory diseases.

What Are Latest Mergers And Acquisitions In The Familial Mediterranean Fever Pharmaceuticals Market?

In January 2024, Swedish Orphan Biovitrum AB, a Sweden-based manufacturer of Interleukin-1 inhibitors, partnered with Acino International AG. The partnership enables Acino to distribute Sobi’s specialized rare disease treatments exclusively in Kazakhstan, expanding access to innovative therapies. Acino International AG is a Switzerland-based pharmaceutical company specializing in developing, manufacturing, and distributing high-quality generic and specialty medicines.

Regional Insights

Middle East was the largest region in the familial mediterranean fever pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Familial Mediterranean Fever Pharmaceuticals Market?

The familial mediterranean fever pharmaceuticals market consists of sales of NSAIDs, corticosteroids, immunosuppressants, disease-modifying antirheumatic drugs, and pain management medications used to manage inflammation and prevent complications in familial mediterranean fever patients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Familial Mediterranean Fever Pharmaceuticals Market Report 2026?

The familial mediterranean fever pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the familial mediterranean fever pharmaceuticals industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.